Posted by Michael Wonder on 26 Jun 2024
Tagrisso with the addition of chemotherapy approved in China as first-line treatment for patients with EGFR-mutated advanced lung cancer
26 June 2024 - Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by nearly half versus standard of care among Chinese patients
AstraZeneca’s Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in China for the first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer whose tumours have exon 19 deletions or exon 21 (L858R) mutations.
